Characterization of Small Molecule ETS Transcription Factor Binders Nicole M. Martinez Marius S. Pop and Levi A. Garraway Cancer Biology Program.

Slides:



Advertisements
Similar presentations
Structural Bioinformatics in Drug Discovery
Advertisements

Genomic DNA Variation Computer-Aided Discovery Methods Baylor College of Medicine course Term 3, 2010/2011 Lecture on Wednesday, February 2 nd,
High-Throughput Bioscience Center (HTBC) Fully automated integrated system: –8, 96 or 384 tip pipettors/pin tools (CaliperLS SciClone ALH 3000) –Robotic.
Chemical Biology 1 – Pharmacology Methods for studying protein function – Loss of Function 1. Gene knockouts 2. Conditional knockouts 3. RNAi.
Gene regulation in cancer 11/14/07. Overview The hallmark of cancer is uncontrolled cell proliferation. Oncogenes code for proteins that help to regulate.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Development of High-throughput Screening Assay for Small Molecule Inhibitor(s) of PIAS1 Bourns College of Engineering Department of Bioengineering Vicente.
Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases.
THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.
Novel Modulators of Ah Receptor Signaling
Microarrays: Tools for Proteomics
Splicing Regulations of CD44v3 in Breast Cancer Metastasis Hayley Baines City of Hope Summer Student Program May 27 – August 1, 2003 Mentor: Tracy Li,
Relating Activating K-Ras Mutations to Small Molecule Sensitivity in Non- Small-Cell Lung Cancer Flavian D. Brown Carleton College Class of 2009.
Protein Arrays By: Nicole Therrien. Overview What Are Protein Arrays? General Scheme Types of Arrays ◦ Analytical  In-depth  Example ◦ Functional 
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Phylogeny in Drug Discovery?
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
Malignant Melanoma and CDKN2A
The Myc Transcription Factor
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Fusion Genes in Cancer Wednesday, June 27th. Outline: Transcription Fusion genes Examples of fusion genes in cancer Summary and conclusions.
Understanding miRNA Turnover: A Study of miRNA Half-Life
A systems biology approach to the identification and analysis of transcriptional regulatory networks in osteocytes Angela K. Dean, Stephen E. Harris, Jianhua.
Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
KIF5B-RET fusions in lung adenocarcinoma The lab of technique department xueqiongZhai
Sequencing TRAF1 in patients with rheumatoid arthritis Bruce C. Jobse Medical and Population Genetics Broad Institute.
FUNCTIONAL GENOMICS REVEAL THAT THE SERINE SYNTHESIS PATHWAY IS ESSENTIAL IN BREAST CANCER Introduction: Tim Butler Spellman Lab.
Kyoto University, Japan
Small molecule-induced pancreatic exocrine transdifferentiation: Assay development Kristin Rose Bridget Wagner, Ph.D. Broad Chemical Biology, Broad Institute.
Therapeutic Targeting of EWS-FLI1: Small Molecule Protein-Protein Interaction Inhibitors Prevent Xenograft Growth Jeffrey Toretsky Department of Oncology.
Finish up array applications Move on to proteomics Protein microarrays.
Here are some CML slides that may be helpful for your presentation.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
Jair L. Siqueira-Neto Assistant Professor
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
Biological Signal Detection for Protein Function Prediction Investigators: Yang Dai Prime Grant Support: NSF Problem Statement and Motivation Technical.
High throughput Protein Measurement Techniques Harin Kanani.
E-beam Size-Dependent Self- Assembly Protein Array.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
Affymetrix microarray analysis by using Cmap By NFU Biology Algorithm lab.
Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.
Project Title Investigators 1 To see TIPS and FAQS for each slide, please look at this template in Notes view.
Predicting patterns of biological performance using chemical substructure features Diego Borges-Rivera 08/04/08.
Chapter 2. Amino acids Protein structure Primary:
Elena Klenova CTCF and BORIS in normal development, epigenetics and tumourigenesis Areas of research: Molecular Oncology Gene regulation Translational.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Molecular Modeling in Drug Discovery: an Overview
Small Molecules that Enhance the Pharmacological Effects of Oligonucleotides Melissa Porter 1, Bing Yang 1, Canhong Cao 1, Xin Ming 1, Emily Hull-Ryde.
HP-SEE In the search of the HDAC-1 inhibitors. The preliminary results of ligand based virtual screening Ilija N. Cvijetić, Ivan O. Juranić,
Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.
Page 1 Transporter Screening -Profacgen. Page 2 Transporters are a group of specialized membrane proteins that power the translocation of numerous substances,
Structural Bioinformatics in Drug Discovery Melissa Passino.
Monica Britton, Ph.D. Sr. Bioinformatics Analyst June 2016 Workshop
Can Drug Discovery Research be Done At An Undergraduate Institution?
SEMINAR 1. Title : Discovery of Protein-Protein Interaction Modulators Using Affinity-Based High-Throughput Screening 2. Speaker : Hyun-Suk Lim (포항공대 (POSTECH))
Ke Xu, Ph.D. Putuo Hospital and Cancer Institute,
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
Structural Bioinformatics in Drug Discovery
Pick a Gene Assignment 4 Requirements
RNA Sequencing Approaches to Identify Novel Biomarkers for Venous Thromboembolism (VTE) in Lung Cancer Tamara A. Sussman MD1, Mohamed Abazeed MD PhD1,
RNA Identity Crisis: Hepatitis B Walks the LINE
Volume 56, Issue 2, Pages (August 2009)
Volume 27, Issue 3, Pages (March 2015)
Preclinical Accelerators of Precision Medicine Todd R. Golub, M.D.
Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers  Yu Chen, Charles L. Sawyers  Cancer Cell  Volume.
Personalized Medicine: Patient-Predictive Panel Power
Establishment of monoclonal SMN2-GFP reporter line in HEK293.
Protein expression profile in a dasatinib-resistant cell line.
An isogenic cell line screen reveals genomic drivers of drug response.
Presentation transcript:

Characterization of Small Molecule ETS Transcription Factor Binders Nicole M. Martinez Marius S. Pop and Levi A. Garraway Cancer Biology Program

Targeted Therapy in Cancer “Druggable” targets –Obvious active site Kinases Other enzymes “Undruggable” targets –No obvious pocket DOI: /nrd2275

Many “Driver” Cancer Proteins are Currently “Undruggable” Example: Oncogenic Transcription Factors –ETS Transcription Factors Translocated in >50% of prostate cancers ETV1 ERG Otis Brawley, National Cancer Institute Prostate Tumor

ETS Transcription Factor Role in Prostate Cancer /ETV1 doi: /nm

Can we develop a therapeutic?

DMSO stock solutions protein-small molecule interaction on a microarray aMouse-IgG-Cy5 ETV1 fluorescent features reveal putative binding interactions Small-Molecule Microarrays (SMMs) ha.11 Lysates expressing target protein αHA MITF ETV1 ERG truncated ERG full

f = microarray feature median pixel intensity b = local background median pixel intensity x cpd = f - b Z* Overlay of GAL File Z* =  cpd - µ mock  mock ( 1+1+ )  cpd 0.96 From Raw Data to Hits

ETV1 Selection of Hits ZScoreA ZScoreB ZScoreC CompositeZ

ChemBank: Tool for Filtering Compounds

List of ETS “Hit” Compounds *LibraryHEK-293T cell lysate MITFETV1ERGtERG NPC PDI NPC: Natural Products and commercials (Including FDA approved drugs) library PDI: Psychiatric Disease Initiative compounds *10,800 compounds per library

Assess Inhibitory Capabilities by Luciferase Assays ETSLuciferase ERG rep rep + ERG rep + ERG + compound Fold

Lead Compounds Cpd1 Cpd2

Assess Inhibitory Capabilities by Luciferase Assays ETSLuciferase ERG rep rep + ERG rep + ERG + compound Fold

Dud Compounds Ctrl DMSO ERG cpds A B C D MITFETV1 Ctrl ERG cpds Ctrl tERG cpds A B C D MITF ETV1

Conclusions SMM allow us to find binders Luciferase assays allow us to determine inhibitory capabilities Future work –Surface Plasmon Resonance –Screen w/ more compounds

Acknowledgements Mentors Marius Pop, PhD Levi Garraway, MD, PhD Collaborators Angela Koehler, PhD Jason Fuller Summer Research Program in Genomics Shawna Young Lucia Vielma Bruce Birren, PhD

ETS Fusion Products Exon 1 of TMPRSS2 with the beginning of exon 4 of ETV1 Exons 1 and 2 of TMPRSS2 with the beginning of exon 4 of ETV1 Exon 1 of TMPRSS2 with the beginning of exon 4 of ERG